Revenue Growth is Accelerating at 3M | MMM Stock Analysis
Summary
Parkev evaluates 3M's current investment appeal in light of its significant restructuring efforts, which include spinning off commodity-like business segments to focus on higher-margin products. Parkev notes that while these changes initially reduced total revenue from $35 billion to $25 billion, they have successfully accelerated organic revenue growth. Parkev highlights management's objective to return operating margins to 25% by utilizing price increases, reducing the number of manufacturing plants, and implementing artificial intelligence to streamline administrative functions such as finance and HR.
However, Parkev concludes that the stock's valuation does not currently offer a margin of safety. Parkev conducts a discounted cash flow (DCF) analysis using a weighted average cost of capital (WACC) to estimate a fair value of $143 per share, which is roughly 12% below the current market price of $163. Parkev also points out that the forward price-to-earnings (P/E) ratio of 16.6 is at the upper end of its historical range, indicating that the market has already priced in much of the recovery optimism. Consequently, Parkev suggests that it is not yet the right time to buy the stock.
Mentioned Stocks
Reasoning: Parkev notes that 3M is successfully restructuring by exiting low-margin 'commodity-like' businesses to improve its operating margins toward a 25% target. However, Parkev's valuation analysis, including a discounted cash flow model, estimates a fair value of $143, which is significantly lower than the current market price of $163. Parkev argues that because the forward P/E of 16.6 is at the high end of the historical range, it is better to wait for a price pullback or further confirmation of margin improvements before buying.